世界の高脂血症治療薬市場は、2023年から2030年の予測期間にわたって健全な成長率で成長すると予想されています。高脂血症治療薬は、脂質低下薬としても知られ、血中の高レベルの脂質（脂肪）、特にコレステロールとトリグリセリドを管理および治療するために使用される薬剤です 高脂血症は脂質レベルの上昇を特徴とする状態であり、心臓発作や脳卒中などの心血管疾患のリスク増加につながる可能性があります。高脂血症治療薬市場は、心血管疾患の有病率の上昇や世界中での高脂血症の有病率の上昇などの要因により拡大しています。
高脂血症の有病率の上昇は、主に不健康なライフスタイル、座りっぱなしの習慣、不適切な食事の選択に起因しており、脂質低下薬の需要が高まっています。世界保健機関 (WHO) は、高コレステロール血症により年間 260 万人以上が死亡していると推定しています。さらに、高コレステロールとしても知られる高脂血症は、心臓病や脳卒中などの心血管疾患の重大な危険因子です。世界中で心血管疾患の有病率が上昇していることが、高脂血症治療薬の成長の原動力となっています。米国心臓病学会の報告によると、2030年までに心血管疾患と診断されるアメリカ人は約2,900万人となり、2021年の695万人から増加するでしょう。2020年には世界中で2億4,410万人が虚血性心疾患を抱えて暮らしていました。したがって、心血管疾患の有病率の上昇が市場の成長を推進しています。 さらに、医薬品開発の臨床試験の増加と医療費の増加により、市場成長の新たな機会が生まれています。ただし、さまざまな治療法の利用可能性、副作用、安全性への懸念により、2023年から2030年の予測期間を通じて市場の成長が抑制されます。
世界の高脂血症治療薬市場調査の対象となる主要地域には、アジア太平洋、北アメリカ、ヨーロッパ、ラテンアメリカ、中東・アフリカが含まれます。北アメリカは、主要な市場プレーヤーの優位性、心血管疾患の有病率の上昇、医薬品開発の進歩、この地域での臨床試験活動の数と医療費の増加により、2022年の市場を支配しました 一方、アジア太平洋地域では、心臓病の有病率の上昇、医療費の増加、医療費の増加、地域への政府の積極的な参加などの要因により、大幅な成長が見込まれています。
この調査の目的は、近年のさまざまなセグメントおよび国の市場規模を定義し、今後数年間の市場規模を予測することです。この報告書は、調査に参加している国の業界の定性的および定量的側面の両方を組み込むように設計されています。
このレポートは、市場の将来の成長を定義する推進要因や課題などの重要な側面に関する詳細情報も提供します。さらに、競争環境と主要企業の製品提供の詳細な分析とともに、利害関係者が投資できるミクロ市場における潜在的な機会も組み込まれています。
目次
Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Hyperlipidemia Drugs Market, by Region, 2020-2030 (USD Billion)
1.2.2. Hyperlipidemia Drugs Market, by Drug Class, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Hyperlipidemia Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Hyperlipidemia Drugs Market Dynamics
3.1. Hyperlipidemia Drugs Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of cardiovascular diseases
3.1.1.2. Rise in prevalence of hyperlipidemia across the globe
3.1.2. Market Challenges
3.1.2.1. Availability of different treatments
3.1.2.2. Adverse effects and safety concerns
3.1.3. Market Opportunities
3.1.3.1. Increasing clinical trials on drug development
3.1.3.2. Rising healthcare expenditure
Chapter 4. Global Hyperlipidemia Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Hyperlipidemia Drugs Market, by Drug Class
5.1. Market Snapshot
5.2. Global Hyperlipidemia Drugs Market by Drug Class, Performance - Potential Analysis
5.3. Global Hyperlipidemia Drugs Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
5.4. Hyperlipidemia Drugs Market, Sub Segment Analysis
5.4.1. Statins
5.4.2. Bile Acid Sequestrants
5.4.3. Cholesterol Absorption Inhibitors
5.4.4. Fibric Acid Derivatives
5.4.5. PCSK9 Inhibitors
5.4.6. Combination
5.4.7. Miscellaneous
Chapter 6. Global Hyperlipidemia Drugs Market, Regional Analysis
6.1. Top Leading Countries
6.2. Top Emerging Countries
6.3. Hyperlipidemia Drugs Market, Regional Market Snapshot
6.4. North America Hyperlipidemia Drugs Market
6.4.1. U.S. Hyperlipidemia Drugs Market
6.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
6.4.2. Canada Hyperlipidemia Drugs Market
6.5. Europe Hyperlipidemia Drugs Market Snapshot
6.5.1. U.K. Hyperlipidemia Drugs Market
6.5.2. Germany Hyperlipidemia Drugs Market
6.5.3. France Hyperlipidemia Drugs Market
6.5.4. Spain Hyperlipidemia Drugs Market
6.5.5. Italy Hyperlipidemia Drugs Market
6.5.6. Rest of Europe Hyperlipidemia Drugs Market
6.6. Asia-Pacific Hyperlipidemia Drugs Market Snapshot
6.6.1. China Hyperlipidemia Drugs Market
6.6.2. India Hyperlipidemia Drugs Market
6.6.3. Japan Hyperlipidemia Drugs Market
6.6.4. Australia Hyperlipidemia Drugs Market
6.6.5. South Korea Hyperlipidemia Drugs Market
6.6.6. Rest of Asia Pacific Hyperlipidemia Drugs Market
6.7. Latin America Hyperlipidemia Drugs Market Snapshot
6.7.1. Brazil Hyperlipidemia Drugs Market
6.7.2. Mexico Hyperlipidemia Drugs Market
6.8. Middle East & Africa Hyperlipidemia Drugs Market
6.8.1. Saudi Arabia Hyperlipidemia Drugs Market
6.8.2. South Africa Hyperlipidemia Drugs Market
6.8.3. Rest of Middle East & Africa Hyperlipidemia Drugs Market
Chapter 7. Competitive Intelligence
7.1. Key Company SWOT Analysis
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Amgen Inc.
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Recent Developments
7.3.2. AstraZeneca PLC
7.3.3. Daiichi Sankyo Company Limited
7.3.4. Eli Lilly and Company
7.3.5. Esperion Therapeutics Inc
7.3.6. GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
7.3.7. Immuron Limited
7.3.8. Ionis Pharmaceuticals Inc.
7.3.9. Merck & Co. Inc.
7.3.10. Sanofi S.A.
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes
8.3. Research Assumption
List of Tables
TABLE 1. Global Hyperlipidemia Drugs Market, report scope
TABLE 2. Global Hyperlipidemia Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Hyperlipidemia Drugs Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
TABLE 4. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 5. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Hyperlipidemia Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Hyperlipidemia Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. U.S. Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 16. U.S. Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. Canada Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 18. Canada Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 20. UK Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 21. UK Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 23. Germany Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 24. Germany Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 26. France Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 27. France Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 29. Italy Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 30. Italy Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 32. Spain Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 33. Spain Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 35. RoE Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 36. RoE Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 38. China Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 39. China Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 41. India Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 42. India Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 44. Japan Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 45. Japan Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 47. South Korea Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 48. South Korea Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 50. Australia Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 51. Australia Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 53. RoAPAC Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 54. RoAPAC Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 56. Brazil Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 57. Brazil Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 59. Mexico Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 60. Mexico Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 62. RoLA Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 63. RoLA Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 65. Saudi Arabia Hyperlipidemia Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 66. South Africa Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. RoMEA Hyperlipidemia Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 68. List of secondary sources, used in the study of global Hyperlipidemia Drugs Market
TABLE 69. List of primary sources, used in the study of global Hyperlipidemia Drugs Market
TABLE 70. Years considered for the study
TABLE 71. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
FIG 1. Global Hyperlipidemia Drugs Market, research methodology
FIG 2. Global Hyperlipidemia Drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Hyperlipidemia Drugs Market, key trends 2022
FIG 5. Global Hyperlipidemia Drugs Market, growth prospects 2023-2030
FIG 6. Global Hyperlipidemia Drugs Market, porters 5 force model
FIG 7. Global Hyperlipidemia Drugs Market, pest analysis
FIG 8. Global Hyperlipidemia Drugs Market, value chain analysis
FIG 9. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Hyperlipidemia Drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Hyperlipidemia Drugs Market, regional snapshot 2020 & 2030
FIG 15. North America Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
FIG 16. Europe Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Hyperlipidemia Drugs Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
